A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Amicus Therapeutics Corporation
Start Date
February 13, 2019
End Date
April 30, 2024
Administered By
Pediatrics, Medical Genetics
Awarded By
Amicus Therapeutics Corporation
Start Date
February 13, 2019
End Date
April 30, 2024